Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies

Annals of Emergency Medicine

Volumn 37, Issue 2, 2001, Pages 189-195

  Seifert, Steven A ^a,b   Boyer, Leslie V ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; SNAKE VENOM ANTISERUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; ENVENOMATION; IMMUNOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RECURRENT DISEASE; SNAKEBITE; SYMPTOM; TISSUE INJURY;

EID: 0035130797     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2001.113135     Document Type: Conference Paper

References (49)

1. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon
2. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming
3. Relationship of venom effects to venom antigen and antivenom serum concentrations in a patient with Crotalus atrox enevenomation treated with a Fab antivenom
4. Recurrence of local symptoms of crotalid envenomation in ovine Fab antivenom treated patients
5. Prevention and Treatment of recurrent local symptoms in crotalid envenomation treated with ovine Fab
6. Recurrent and persistent coagulopathy following pit viper envenomation
7. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity
8. Pharmacokinetics of three commercial antivenoms in patients envenomed by the malayan pit viper, Calloselasma rhodostoma, in Thailand
9. Envenomation by the northern blacktail rattlesnake (Crotalus molossus molossus) report of two cases and the in vitro effects of the venom on fibrinolysis and platelet aggregation
10. First clinical experiences with a new ovine Fab' Echis ocellatus snake bite antivenom in Nigeria: Randomized comparative trial with Institute Pasteur serum (IPSER) Africa antivenom
11. Phase 1 study on human monoclonal antibody against cytomegalovirus: Pharmacokinetics and immunogenicity
12. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice
13. Kinetics of the Fab fragments of digoxin anti-bodies and of bound digoxin in patients with severe digoxin intoxication
14. Snake F(ab')2 antivenom from hyperimmunized horse: Pharmacokinetics following intravenous and intramuscula-administrations in rabbits
15. Contrasting rates of reversal of digoxin toxicity by digoxin-specific IgG and Fab' fragments
16. The role of the kidney in the catabolism of Bence-Jones proteins and immunoglobin fragments
17. Pharmacokinetics of heterologous and homologous immunoglobulin G,F(ab')2 and Fab after intravenous administration in the rat
18. Permselectivity of the glomerular capillary wall to macromolecules. II. Experimental studies in rat using neutral dextran
19. Serum disappearance and catabolism of homologous immuno-globulin fragments in rats
20. Pharmacokinetics and toxicity of high doses of antibody Fab fragments in rats
21. Glomerular filtration of proteins: Clearance of anionic, neutral, and cationic horseradish peroxidase in the rat
22. Glomerular sieving of anionic and neutral bovine albumins in proteinuric rats
23. Neurotoxicity haemostatic disturbances and haemelytic anaemia after a bite by a Tunisian saw-scaled or carpet viper (Echis 'pyramidum'-complex): Failure of antivenom treatment
24. Circulating immune complexes, complement activation kinetics and serum sickness following treatment with heterologous anti-snake venom globulin
25. Levels of therapeutic antivenin and venom in a human snakebite victim
26. Enzymes in snake venom
27. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs
28. F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model
29. Similar effectiveness of Fab' and F(ab')2 antivenoms in the neutralization of hemorrhagic activity of Vipera berus snake venom in mice
30. Neutralization of local tissue damage induced by Bothrops asper (terciopelo) snake venom
31. Humeral immune response against OKT3
32. Human trial of an affinity purified antibody fragment for snake venom poisoning
33. Pharmacokinetic analysis of a crotalid Fab antivenom and theoretical considerations for the prevention of coagulopathic recurrence
34. Pharmacokinetic analysis of a crotalid Fab antivenom and theoretical considerations for the prevention of coagulopathic recurrence
35. Fibrinolytic enzyme(s) in Western diamondback rattlesnake (Crotalus atrox) venom
36. Characterization of snake venom components acting on blood coagulation and platelet function
37. DC-like syndrome after envenomation by the snake, Crotalus horridus horridus
38. Purpura following timber rattlesnake (Crotalus horridus horridus) envenomation
39. Profound thrombocytopenia associated with Crotalus ruber ruber envenomation: A clinical case
40. Fibrinogenolytic afibrinogenemia after envenomation by Western diamondback rattlesnake (Crotalus atrox)
41. Envenomation coagulopathy from snakebites
42. Blood platelet studies in man and rabbits following Crotalus envenomation
43. Preclinical assessment of immunoreactivity of a new purified equine F(ab')2 against European viper venom
44. The pharmacokinetic characteristic of glycolated humanized anti-Tac Fab' are determine by their isoelectric points
45. Altered pharmacokinetic and tumour localization properties of Fab' fragments of a murine monclonal anti-CEA antibody by covalent modification with low molecular weight dextran
46. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins
47. Development of a sensitive radioimmunoassay for Fab fragments: Application to Fab pharmacokinetics in humans
48. Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment
49. Digoxin intoxication in a patient with end-stage renal disease: Efficiency of digoxin-specific Fab antibody fragments and peritoneal dialysis